Wynzora^®️ Cream

(calcipotriene and betamethasone dipropionate)
Cream, 0.005%/0.064%

APPROVED IN THE US AND EUROPE FOR ADULTS WITH PLAQUE PSORIASIS

Wynzora^®️ Cream is a novel topical treatment for plaque psoriasis in adults uniquely formulated using PAD Technology™. It provides a unique combination of fast and high efficacy, a favorable safety profile and is tailormade to optimize treatment convenience in a single product.

Please click here to see more about Wynzora^®️ Cream in the US including mode of action involving the hallmark IL-23 and IL-17 immune axis and TNF-α expression, leading to epidermal hyperproliferation inflammation and itch.

Please click here to obtain the FDA-approved Full Prescribing Information for the US.

Please click here to obtain a summary of product characteristics for countries in EU.